DE60100740T4 - Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten - Google Patents
Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten Download PDFInfo
- Publication number
- DE60100740T4 DE60100740T4 DE60100740T DE60100740T DE60100740T4 DE 60100740 T4 DE60100740 T4 DE 60100740T4 DE 60100740 T DE60100740 T DE 60100740T DE 60100740 T DE60100740 T DE 60100740T DE 60100740 T4 DE60100740 T4 DE 60100740T4
- Authority
- DE
- Germany
- Prior art keywords
- gly
- asp
- use according
- ala
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 65
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 31
- 208000024172 Cardiovascular disease Diseases 0.000 title description 2
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000003869 thrombin derivative Substances 0.000 claims abstract description 24
- 239000003814 drug Substances 0.000 claims abstract description 23
- 230000002491 angiogenic effect Effects 0.000 claims abstract description 17
- 208000037803 restenosis Diseases 0.000 claims abstract description 17
- 210000005003 heart tissue Anatomy 0.000 claims abstract description 12
- 206010053648 Vascular occlusion Diseases 0.000 claims abstract description 9
- 208000021331 vascular occlusion disease Diseases 0.000 claims abstract description 9
- 230000004936 stimulating effect Effects 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract 6
- 230000001737 promoting effect Effects 0.000 claims abstract 2
- 210000004204 blood vessel Anatomy 0.000 claims description 21
- 108090000166 Thrombin receptors Proteins 0.000 claims description 20
- 102000003790 Thrombin receptors Human genes 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- 229920000954 Polyglycolide Polymers 0.000 claims description 15
- 108020002447 serine esterase Proteins 0.000 claims description 14
- 102000005428 serine esterase Human genes 0.000 claims description 14
- 238000009472 formulation Methods 0.000 claims description 12
- 239000004633 polyglycolic acid Substances 0.000 claims description 11
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 10
- 239000004626 polylactic acid Substances 0.000 claims description 10
- 238000002399 angioplasty Methods 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- HZKLCOYAVAAQRD-VGMNWLOBSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1r)-1-carboxyethyl]amino]-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N HZKLCOYAVAAQRD-VGMNWLOBSA-N 0.000 claims description 4
- 108010086780 arginyl-glycyl-aspartyl-alanine Proteins 0.000 claims description 4
- 239000011859 microparticle Substances 0.000 claims description 4
- 210000003556 vascular endothelial cell Anatomy 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 23
- 230000000250 revascularization Effects 0.000 abstract description 8
- 210000002889 endothelial cell Anatomy 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 17
- 239000004005 microsphere Substances 0.000 description 16
- 108090000190 Thrombin Proteins 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 230000005012 migration Effects 0.000 description 10
- 238000013508 migration Methods 0.000 description 10
- 229960004072 thrombin Drugs 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000000302 ischemic effect Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000004165 myocardium Anatomy 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229920002627 poly(phosphazenes) Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 208000034827 Neointima Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000001270 agonistic effect Effects 0.000 description 3
- 108010016628 ameroid Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000011555 rabbit model Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000004231 tunica media Anatomy 0.000 description 3
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 2
- ZLUFYQVHJAVDHU-NSCUHMNNSA-N (6e)-2-methyl-2,3-dihydro-1,4-dioxocine-5,8-dione Chemical class CC1COC(=O)\C=C\C(=O)O1 ZLUFYQVHJAVDHU-NSCUHMNNSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229960001089 dobutamine Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000000260 hypercholesteremic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000003562 morphometric effect Effects 0.000 description 2
- 238000013425 morphometry Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 238000013310 pig model Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- VBISQLWPGDULSX-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 VBISQLWPGDULSX-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODYCAZSSUVCHNU-XLAORIBOSA-N Laurencin Natural products CC[C@H]1C[C@H](CC=CC[C@@H]1Br)[C@@H](CC=CC#C)OC(=O)C ODYCAZSSUVCHNU-XLAORIBOSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010252 digital analysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000001542 lens epithelial cell Anatomy 0.000 description 1
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000030114 positive regulation of endothelial cell proliferation Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- XZNXVSDNACTASG-RZNNTOFGSA-M sodium;3,5-diacetamido-2,4,6-triiodobenzoate;3,5-diacetamido-2,4,6-triiodobenzoic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound [Na+].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I XZNXVSDNACTASG-RZNNTOFGSA-M 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002345 thrombinlike Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000004218 vascular function Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Immunology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Prostheses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21758300P | 2000-07-12 | 2000-07-12 | |
| US217583P | 2000-07-12 | ||
| PCT/US2001/021944 WO2002004008A2 (en) | 2000-07-12 | 2001-07-12 | Methods of therapy with thrombin derived peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60100740T2 DE60100740T2 (de) | 2004-07-01 |
| DE60100740T4 true DE60100740T4 (de) | 2005-01-27 |
Family
ID=22811661
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60100740T Expired - Lifetime DE60100740T4 (de) | 2000-07-12 | 2001-07-12 | Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten |
| DE60100740A Expired - Lifetime DE60100740D1 (de) | 2000-07-12 | 2001-07-12 | Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60100740A Expired - Lifetime DE60100740D1 (de) | 2000-07-12 | 2001-07-12 | Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US6867190B2 (enExample) |
| EP (1) | EP1253937B1 (enExample) |
| JP (2) | JP3618736B2 (enExample) |
| CN (1) | CN100500211C (enExample) |
| AT (1) | ATE249238T1 (enExample) |
| AU (2) | AU2001278907B2 (enExample) |
| CA (1) | CA2415778A1 (enExample) |
| DE (2) | DE60100740T4 (enExample) |
| TW (1) | TWI257307B (enExample) |
| WO (1) | WO2002004008A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6774278B1 (en) * | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| US6346510B1 (en) * | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| AU2002241917B2 (en) * | 2000-07-12 | 2006-06-15 | The Board Of Regents, The University Of Texas System | Thrombin derived peptides for promoting cardiac tissue repair |
| TWI257307B (en) | 2000-07-12 | 2006-07-01 | Orthologic Corp | Pharmaceutical composition for cardiac tissue repair |
| US7803149B2 (en) * | 2002-07-12 | 2010-09-28 | Cook Incorporated | Coated medical device |
| DE10115740A1 (de) * | 2001-03-26 | 2002-10-02 | Ulrich Speck | Zubereitung für die Restenoseprophylaxe |
| CA2511223A1 (en) * | 2002-01-16 | 2003-07-31 | The Board Of Regents, The University Of Texas System | Thrombin derived peptides for promoting cardiac tissue repair |
| AU2003256343B2 (en) * | 2002-07-02 | 2006-12-21 | Orthologic Corp. | Thrombin peptide derivatives |
| EP1539800B1 (en) * | 2002-07-02 | 2007-05-23 | Orthologic Corp. | Thrombin peptide derivative dimers |
| DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
| AU2004211592B2 (en) | 2003-02-12 | 2008-04-10 | Monsanto Technology Llc | Cotton event MON 88913 and compositions and methods for detection thereof |
| US8383158B2 (en) * | 2003-04-15 | 2013-02-26 | Abbott Cardiovascular Systems Inc. | Methods and compositions to treat myocardial conditions |
| DE602004005564T2 (de) * | 2003-12-31 | 2007-12-13 | Orthologic Corp., Tempe | Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten |
| CA2576971A1 (en) * | 2004-08-20 | 2006-03-02 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| US9539410B2 (en) | 2005-04-19 | 2017-01-10 | Abbott Cardiovascular Systems Inc. | Methods and compositions for treating post-cardial infarction damage |
| US20080125745A1 (en) | 2005-04-19 | 2008-05-29 | Shubhayu Basu | Methods and compositions for treating post-cardial infarction damage |
| JP2006321740A (ja) * | 2005-05-18 | 2006-11-30 | Kanazawa Univ | 虚血後血管新生促進剤 |
| US9242005B1 (en) | 2006-08-21 | 2016-01-26 | Abbott Cardiovascular Systems Inc. | Pro-healing agent formulation compositions, methods and treatments |
| CA2663547C (en) * | 2006-09-22 | 2020-08-25 | Orthologic Corp. | Method of treating endothelial dysfunction |
| US9005672B2 (en) | 2006-11-17 | 2015-04-14 | Abbott Cardiovascular Systems Inc. | Methods of modifying myocardial infarction expansion |
| US8227412B2 (en) * | 2007-03-29 | 2012-07-24 | Tsopanoglou Nikos E | Bioactive parstatin peptides and methods of use |
| EP2155236A1 (en) * | 2007-04-10 | 2010-02-24 | The Board of Regents,The University of Texas System | Combination therapy for cardiac revascularization and cardiac repair |
| US8202528B2 (en) * | 2007-06-05 | 2012-06-19 | Abbott Cardiovascular Systems Inc. | Implantable medical devices with elastomeric block copolymer coatings |
| GB2450747A (en) * | 2007-07-06 | 2009-01-07 | Univ Sheffield | Treatment of sensorineural hearing loss |
| US8586398B2 (en) * | 2008-01-18 | 2013-11-19 | Miasole | Sodium-incorporation in solar cell substrates and contacts |
| AU2009229395A1 (en) * | 2008-03-26 | 2009-10-01 | The Board Of Regents, The University Of Texas System | Method of treating degenerative diseases |
| US20110117075A1 (en) * | 2008-03-26 | 2011-05-19 | Orthologic Corp. | Thrombin derived peptides for smooth muscle relaxation |
| EP2268304A2 (en) * | 2008-03-26 | 2011-01-05 | Orthologic Corp. | Methods for treating acute myocardial infarction |
| WO2009120307A2 (en) * | 2008-03-26 | 2009-10-01 | Orthologic Corp. | Method of treating peripheral arterial disease |
| US20110319340A1 (en) * | 2008-09-19 | 2011-12-29 | The Board Of Regents, The University Of Texas System | Methods for treating cancer |
| US20130101574A1 (en) * | 2010-06-11 | 2013-04-25 | Darrell H. Carney | Methods of using thrombin peptide derivatives |
| GB201314312D0 (en) * | 2013-08-09 | 2013-09-25 | Regentec Ltd | Composition and delivery system |
| US20160039876A1 (en) | 2014-03-28 | 2016-02-11 | Claresa Levetan | Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide |
| US10220078B2 (en) | 2014-06-11 | 2019-03-05 | The Board Of Regents Of The University Of Texas System | Methods of using thrombin derivatives to treat medulloblastoma |
| WO2020210087A1 (en) * | 2019-04-12 | 2020-10-15 | Affirmed Pharma, Llc | Rusalatide acetate compositions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5352664A (en) * | 1986-10-31 | 1994-10-04 | Board Of Regents, The University Of Texas System | Thrombin derived polypeptides; compositions and methods for use |
| US5244460A (en) * | 1991-11-27 | 1993-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method to foster myocardial blood vessel growth and improve blood flow to the heart |
| EP0697883A1 (en) | 1993-04-29 | 1996-02-28 | Washington University | Use of platelet-derived growth factor to improve collateral circulation |
| ATE273322T1 (de) * | 1995-10-24 | 2004-08-15 | Chemo Sero Therapeut Res Inst | Tfpi-verwandte peptide die das wachstums von glatten muskelzellen inhibieren |
| US5912229A (en) * | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| US6197751B1 (en) * | 1997-11-10 | 2001-03-06 | The United States Of America As Represented By The Department Of Health And Human Services | Thymosin α1 promotes tissue repair, angiogenesis and cell migration |
| US6033436A (en) * | 1998-02-17 | 2000-03-07 | Md3, Inc. | Expandable stent |
| JP2002512200A (ja) | 1998-04-17 | 2002-04-23 | アンジオジェニックス， インコーポレイテッド | 治療的な脈管形成因子およびその使用方法 |
| CA2340593C (en) | 1998-10-26 | 2012-05-08 | Kari Alitalo | Use of vegf-c or vegf-d gene or protein to prevent restenosis |
| US6363938B2 (en) * | 1998-12-22 | 2002-04-02 | Angiotrax, Inc. | Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth |
| TWI257307B (en) * | 2000-07-12 | 2006-07-01 | Orthologic Corp | Pharmaceutical composition for cardiac tissue repair |
-
2001
- 2001-07-11 TW TW090116938A patent/TWI257307B/zh not_active IP Right Cessation
- 2001-07-12 AU AU2001278907A patent/AU2001278907B2/en not_active Ceased
- 2001-07-12 JP JP2002508462A patent/JP3618736B2/ja not_active Expired - Fee Related
- 2001-07-12 DE DE60100740T patent/DE60100740T4/de not_active Expired - Lifetime
- 2001-07-12 EP EP01957136A patent/EP1253937B1/en not_active Expired - Lifetime
- 2001-07-12 AU AU7890701A patent/AU7890701A/xx active Pending
- 2001-07-12 DE DE60100740A patent/DE60100740D1/de not_active Expired - Lifetime
- 2001-07-12 US US09/904,090 patent/US6867190B2/en not_active Expired - Lifetime
- 2001-07-12 AT AT01957136T patent/ATE249238T1/de active
- 2001-07-12 CN CNB018154581A patent/CN100500211C/zh not_active Expired - Fee Related
- 2001-07-12 CA CA002415778A patent/CA2415778A1/en not_active Abandoned
- 2001-07-12 WO PCT/US2001/021944 patent/WO2002004008A2/en not_active Ceased
-
2002
- 2002-01-16 US US10/050,611 patent/US6861407B2/en not_active Expired - Fee Related
-
2004
- 2004-08-09 JP JP2004232356A patent/JP2005036007A/ja not_active Withdrawn
- 2004-09-30 US US10/957,427 patent/US7034001B2/en not_active Expired - Fee Related
-
2005
- 2005-12-02 US US11/293,495 patent/US7214661B2/en not_active Expired - Fee Related
-
2007
- 2007-04-13 US US11/787,114 patent/US7732411B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60100740D1 (de) | 2003-10-16 |
| JP3618736B2 (ja) | 2005-02-09 |
| TWI257307B (en) | 2006-07-01 |
| CN1455678A (zh) | 2003-11-12 |
| JP2004502739A (ja) | 2004-01-29 |
| CN100500211C (zh) | 2009-06-17 |
| EP1253937A2 (en) | 2002-11-06 |
| AU7890701A (en) | 2002-01-21 |
| HK1060302A1 (zh) | 2004-08-06 |
| WO2002004008A2 (en) | 2002-01-17 |
| US7034001B2 (en) | 2006-04-25 |
| AU2001278907B2 (en) | 2004-10-21 |
| US6867190B2 (en) | 2005-03-15 |
| US20060134167A1 (en) | 2006-06-22 |
| WO2002004008A3 (en) | 2002-08-22 |
| US6861407B2 (en) | 2005-03-01 |
| US20050153884A1 (en) | 2005-07-14 |
| US20080131474A1 (en) | 2008-06-05 |
| DE60100740T2 (de) | 2004-07-01 |
| US7214661B2 (en) | 2007-05-08 |
| EP1253937B1 (en) | 2003-09-10 |
| US20020061852A1 (en) | 2002-05-23 |
| US20020187933A1 (en) | 2002-12-12 |
| JP2005036007A (ja) | 2005-02-10 |
| US7732411B2 (en) | 2010-06-08 |
| CA2415778A1 (en) | 2002-01-17 |
| ATE249238T1 (de) | 2003-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60100740T4 (de) | Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten | |
| DE69735763T2 (de) | Intravaskuläre verabreichung von medikamenten durch elektroporation | |
| DE69219418T2 (de) | Zusammensetzung zur Revitalisierung von Nerbgewebe | |
| DE69427908T2 (de) | Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält | |
| DE69332624T2 (de) | WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3 | |
| DE69230670T2 (de) | Zusammensetzungen, die eine blutgerinnselpolymermatrix zur verabreichung von osteogenen proteinen enthalten | |
| JP5383757B2 (ja) | 薬剤放出生分解性繊維インプラント | |
| DE69936212T2 (de) | Hydrogelzusammensetzungen mit kontrollierter Freigabe für die Verabreichung von Wachstumsfaktoren | |
| AU2001278907A1 (en) | Methods of therapy with thrombin derived peptides | |
| DE60101339T2 (de) | Stimulierung des knochenwachstums mit peptidderivaten von thrombin | |
| EP0938342B1 (de) | Injizierbare polymerzusammensetzung zur herstellung eines in-situ-implantats | |
| CH673774A5 (enExample) | ||
| DE69013797T2 (de) | Gehirnspezifische Zubereitung mit gesteuerter Abgabe. | |
| DE69711024T2 (de) | Steuerung des heilungsprozesses | |
| EP1467749B1 (en) | Thrombin derived peptides for promoting cardiac tissue repair | |
| DE3835099A1 (de) | Pharmazeutische zusammensetzung | |
| DE60110247T2 (de) | Angiogenische Tri- oder Tetrapeptide abgeleitet von AcSDKP | |
| AU2002241917B2 (en) | Thrombin derived peptides for promoting cardiac tissue repair | |
| AU2002241917A1 (en) | Thrombin derived peptides for promoting cardiac tissue repair | |
| HK1060302B (en) | Methods of therapy with thrombin derived peptides | |
| TAXI et al. | Jamila CHEDLY1, Sylvia SOARES1, Alexandra MONTEMBAULT2, Ysander von BOXBERG1, Michèle VERON-RAVAILLE1, Christine MOUFFLE1, Marie-Noelle BENASSY1 | |
| HK1078263B (en) | Thrombin derived peptides for promoting cardiac tissue repair |